.

Deeper Knowledge, Faster

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fuji
Harvard Business School
Teva
Novartis
Argus Health
Merck
Queensland Health
Mallinckrodt
Deloitte
Johnson and Johnson

Generated: November 20, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,114,890

« Back to Dashboard

Which drugs does patent 8,114,890 protect, and when does it expire?


Patent 8,114,890 protects AMITIZA and is included in one NDA. There has been one Paragraph IV challenge on Amitiza.

This patent has thirty-seven patent family members in twenty-four countries.

Summary for Patent: 8,114,890

Title:Anti-constipation composition
Abstract: An object of the present invention is to provide an anti-constipation composition containing a halogenated-bi-cyclic compound as an active ingredient in ratio of bi-cyclic/mono-cyclic structure of at least 1:1. The halogenated-bi-cyclic compound is represented by Formula (I): ##STR00001## where X.sub.1 and X.sub.2 are preferably both fluorine atoms. The composition can be used to treat constipation with out substantive side-effects, such as stomachache.
Inventor(s): Ueno; Ryuji (Potomac, MD)
Assignee: Sucampo AG (Zurich, CH)
Application Number:13/274,612
Patent Claim Types:
see list of patent claims
Formulation; Compound; Dosage form;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Sucampo Pharma Llc
AMITIZA
lubiprostone
CAPSULE;ORAL021908-002Apr 29, 2008RXYesNo► Subscribe► SubscribeY
Sucampo Pharma Llc
AMITIZA
lubiprostone
CAPSULE;ORAL021908-001Jan 31, 2006RXYesYes► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 8,114,890

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,414,016 Anti-constipation composition► Subscribe
8,748,454Anti-constipation composition► Subscribe
8,071,613Anti-constipation composition► Subscribe
6,610,732 Anti-constipation composition► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,114,890

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
TaiwanI305147► Subscribe
Russian Federation2278666► Subscribe
Portugal1857105► Subscribe
Portugal1315485► Subscribe
New Zealand524401► Subscribe
Norway332701► Subscribe
Norway20030996► Subscribe
Netherlands300757► Subscribe
MexicoPA03001959► Subscribe
South Korea100918223► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
QuintilesIMS
Colorcon
Harvard Business School
Mallinckrodt
Cipla
Farmers Insurance
Dow
Baxter
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot